Which has preferable valuation and earnings, GOSS or IVVD?

Invivyd has higher revenue and earnings than Gossamer Bio. Invivyd is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gossamer Bio $48.47M 0.75 -$170.37M -$0.79 N/A Invivyd $53.43M 3.97 -$52.49M -$0.31 N/A

Is GOSS or IVVD more profitable?

Invivyd has a net margin of -183.90% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat Invivyd's return on equity. Company Net Margins Return on Equity Return on Assets Gossamer Bio -235.00% N/A -96.70% Invivyd -183.90% -59.89% -48.95%

Does the media refer more to GOSS or IVVD?

In the previous week, Gossamer Bio had 1 more articles in the media than Invivyd. MarketBeat recorded 6 mentions for Gossamer Bio and 5 mentions for Invivyd. Gossamer Bio's average media sentiment score of -0.30 beat Invivyd's score of -0.62 indicating that Gossamer Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gossamer Bio 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Invivyd 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative

Does the media refer more to GOSS or ABOS?

In the previous week, Acumen Pharmaceuticals had 2 more articles in the media than Gossamer Bio. MarketBeat recorded 8 mentions for Acumen Pharmaceuticals and 6 mentions for Gossamer Bio. Acumen Pharmaceuticals' average media sentiment score of 0.20 beat Gossamer Bio's score of -0.30 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gossamer Bio 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Acumen Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer GOSS or YDES?

Gossamer Bio currently has a consensus price target of $3.20, indicating a potential upside of 1,975.23%. Given Gossamer Bio's stronger consensus rating and higher possible upside, analysts clearly believe Gossamer Bio is more favorable than YD Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gossamer Bio 2 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.22 YD Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, GOSS or YDES?

YD Bio has lower revenue, but higher earnings than Gossamer Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gossamer Bio $48.47M 0.75 -$170.37M -$0.79 N/A YD Bio N/A N/A N/A N/A N/A

Is GOSS or YDES more profitable?

YD Bio has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Company Net Margins Return on Equity Return on Assets Gossamer Bio -235.00% N/A -96.70% YD Bio N/A N/A N/A

Does the media refer more to GOSS or YDES?

In the previous week, Gossamer Bio had 3 more articles in the media than YD Bio. MarketBeat recorded 6 mentions for Gossamer Bio and 3 mentions for YD Bio. YD Bio's average media sentiment score of 0.39 beat Gossamer Bio's score of -0.30 indicating that YD Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gossamer Bio 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral YD Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Gossamer Bio (GOSS) Competitors

$0.15 -0.02 (-9.45%)

Closing price 04:00 PM Eastern

Extended Trading

$0.16 +0.00 (+1.17%)

As of 07:59 PM Eastern

Compare

GOSS vs. MOLN, IVVD, ABOS, OKUR, and YDES

Should you buy Gossamer Bio stock or one of its competitors? Gossamer Bio's main competitors and comparable companies include Molecular Partners (MOLN), Invivyd (IVVD), Acumen Pharmaceuticals (ABOS), OnKure Therapeutics (OKUR), and YD Bio (YDES). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Gossamer Bio compare to Molecular Partners?

Molecular Partners (NASDAQ:MOLN) and Gossamer Bio (NASDAQ:GOSS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Molecular Partners has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2.04, indicating that its stock price is 104% more volatile than the broader market.

Molecular Partners has higher earnings, but lower revenue than Gossamer Bio. Molecular Partners is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Molecular Partners	$5.65M	29.34	-$74.41M	-$1.94	N/A
Gossamer Bio	$48.47M	0.75	-$170.37M	-$0.79	N/A

26.6% of Molecular Partners shares are owned by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are owned by institutional investors. 5.9% of Molecular Partners shares are owned by company insiders. Comparatively, 3.7% of Gossamer Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Gossamer Bio had 4 more articles in the media than Molecular Partners. MarketBeat recorded 6 mentions for Gossamer Bio and 2 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 1.43 beat Gossamer Bio's score of -0.30 indicating that Molecular Partners is being referred to more favorably in the media.

Company	Overall Sentiment
Molecular Partners	Positive
Gossamer Bio	Neutral

Molecular Partners has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Molecular Partners	N/A	-66.62%	-54.85%
Gossamer Bio	-235.00%	N/A	-96.70%

Molecular Partners presently has a consensus target price of $8.38, suggesting a potential upside of 104.02%. Gossamer Bio has a consensus target price of $3.20, suggesting a potential upside of 1,975.23%. Given Gossamer Bio's higher probable upside, analysts plainly believe Gossamer Bio is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

Summary

Gossamer Bio beats Molecular Partners on 9 of the 16 factors compared between the two stocks.

How does Gossamer Bio compare to Invivyd?

Gossamer Bio (NASDAQ:GOSS) and Invivyd (NASDAQ:IVVD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

Invivyd has higher revenue and earnings than Gossamer Bio. Invivyd is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	0.75	-$170.37M	-$0.79	N/A
Invivyd	$53.43M	3.97	-$52.49M	-$0.31	N/A

Gossamer Bio currently has a consensus target price of $3.20, indicating a potential upside of 1,975.23%. Invivyd has a consensus target price of $8.00, indicating a potential upside of 1,011.11%. Given Gossamer Bio's higher possible upside, analysts plainly believe Gossamer Bio is more favorable than Invivyd.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Gossamer Bio had 1 more articles in the media than Invivyd. MarketBeat recorded 6 mentions for Gossamer Bio and 5 mentions for Invivyd. Gossamer Bio's average media sentiment score of -0.30 beat Invivyd's score of -0.62 indicating that Gossamer Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gossamer Bio	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Invivyd	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

Gossamer Bio has a beta of 2.04, suggesting that its share price is 104% more volatile than the broader market. Comparatively, Invivyd has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market.

81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 70.4% of Invivyd shares are owned by institutional investors. 3.7% of Gossamer Bio shares are owned by insiders. Comparatively, 12.3% of Invivyd shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Invivyd has a net margin of -183.90% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat Invivyd's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-235.00%	N/A	-96.70%
Invivyd	-183.90%	-59.89%	-48.95%

Summary

Gossamer Bio and Invivyd tied by winning 8 of the 16 factors compared between the two stocks.

How does Gossamer Bio compare to Acumen Pharmaceuticals?

Gossamer Bio (NASDAQ:GOSS) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

Gossamer Bio has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market.

Gossamer Bio presently has a consensus target price of $3.20, suggesting a potential upside of 1,975.23%. Acumen Pharmaceuticals has a consensus target price of $8.00, suggesting a potential upside of 199.63%. Given Gossamer Bio's higher possible upside, equities research analysts plainly believe Gossamer Bio is more favorable than Acumen Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Acumen Pharmaceuticals had 2 more articles in the media than Gossamer Bio. MarketBeat recorded 8 mentions for Acumen Pharmaceuticals and 6 mentions for Gossamer Bio. Acumen Pharmaceuticals' average media sentiment score of 0.20 beat Gossamer Bio's score of -0.30 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gossamer Bio	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Acumen Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Acumen Pharmaceuticals has lower revenue, but higher earnings than Gossamer Bio. Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	0.75	-$170.37M	-$0.79	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A

81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 3.7% of Gossamer Bio shares are held by company insiders. Comparatively, 10.2% of Acumen Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Acumen Pharmaceuticals has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-235.00%	N/A	-96.70%
Acumen Pharmaceuticals	N/A	-136.27%	-81.64%

Summary

Gossamer Bio beats Acumen Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Gossamer Bio compare to OnKure Therapeutics?

OnKure Therapeutics (NASDAQ:OKUR) and Gossamer Bio (NASDAQ:GOSS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

OnKure Therapeutics presently has a consensus price target of $17.50, indicating a potential upside of 338.60%. Gossamer Bio has a consensus price target of $3.20, indicating a potential upside of 1,975.23%. Given Gossamer Bio's higher probable upside, analysts clearly believe Gossamer Bio is more favorable than OnKure Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

In the previous week, Gossamer Bio had 5 more articles in the media than OnKure Therapeutics. MarketBeat recorded 6 mentions for Gossamer Bio and 1 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 1.87 beat Gossamer Bio's score of -0.30 indicating that OnKure Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
OnKure Therapeutics	Very Positive
Gossamer Bio	Neutral

91.0% of OnKure Therapeutics shares are owned by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are owned by institutional investors. 2.2% of OnKure Therapeutics shares are owned by insiders. Comparatively, 3.7% of Gossamer Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

OnKure Therapeutics has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2.04, indicating that its stock price is 104% more volatile than the broader market.

OnKure Therapeutics has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat OnKure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-49.01%	-45.77%
Gossamer Bio	-235.00%	N/A	-96.70%

OnKure Therapeutics has higher earnings, but lower revenue than Gossamer Bio. OnKure Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$59.52M	-$3.50	N/A
Gossamer Bio	$48.47M	0.75	-$170.37M	-$0.79	N/A

Summary

Gossamer Bio beats OnKure Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Gossamer Bio compare to YD Bio?

Gossamer Bio (NASDAQ:GOSS) and YD Bio (NASDAQ:YDES) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

81.2% of Gossamer Bio shares are held by institutional investors. 3.7% of Gossamer Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Gossamer Bio had 3 more articles in the media than YD Bio. MarketBeat recorded 6 mentions for Gossamer Bio and 3 mentions for YD Bio. YD Bio's average media sentiment score of 0.39 beat Gossamer Bio's score of -0.30 indicating that YD Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gossamer Bio	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
YD Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Gossamer Bio currently has a consensus price target of $3.20, indicating a potential upside of 1,975.23%. Given Gossamer Bio's stronger consensus rating and higher possible upside, analysts clearly believe Gossamer Bio is more favorable than YD Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
YD Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

YD Bio has lower revenue, but higher earnings than Gossamer Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	0.75	-$170.37M	-$0.79	N/A
YD Bio	N/A	N/A	N/A	N/A	N/A

YD Bio has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-235.00%	N/A	-96.70%
YD Bio	N/A	N/A	N/A

Summary

Gossamer Bio beats YD Bio on 7 of the 10 factors compared between the two stocks.

Get Gossamer Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GOSS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GOSS vs. The Competition

Export

Metric	Gossamer Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$39.97M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-0.22	10.67	269.06	25.28
Price / Sales	0.75	1,294.08	602.43	91.76
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	-0.29	16.78	12.91	6.24
Net Income	-$170.37M	-$13.32M	$3.45B	$347.60M
7 Day Performance	-13.37%	1.74%	1.12%	1.07%
1 Month Performance	10.06%	1.60%	1.79%	1.03%
1 Year Performance	-92.13%	56.43%	67.69%	20.77%

Gossamer Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GOSS Gossamer Bio	2.4157 of 5 stars	$0.15 -9.5%	$3.20 +1,975.2%	-91.4%	$39.97M	$48.47M	N/A	180	News Coverage Earnings Report
MOLN Molecular Partners	3.2281 of 5 stars	$4.18 +6.4%	$8.38 +100.4%	+10.2%	$158.67M	$5.65M	N/A	180	Short Interest Decrease High Trading Volume
IVVD Invivyd	3.2099 of 5 stars	$0.55 +3.1%	$8.00 +1,350.3%	-13.5%	$157.62M	$53.43M	N/A	100	News Coverage Earnings Report
ABOS Acumen Pharmaceuticals	2.0299 of 5 stars	$2.18 +1.4%	$8.00 +267.0%	+100.8%	$155.29M	N/A	N/A	20	Earnings Report
OKUR OnKure Therapeutics	3.1245 of 5 stars	$4.02 +5.2%	$21.00 +422.4%	+62.5%	$154.31M	N/A	N/A	N/A	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GOSS) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gossamer Bio (GOSS) Competitors

GOSS vs. MOLN, IVVD, ABOS, OKUR, and YDES

How does Gossamer Bio compare to Molecular Partners?

Summary

How does Gossamer Bio compare to Invivyd?

Summary

How does Gossamer Bio compare to Acumen Pharmaceuticals?

Summary

How does Gossamer Bio compare to OnKure Therapeutics?

Summary

How does Gossamer Bio compare to YD Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOSS vs. The Competition

Gossamer Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gossamer Bio (GOSS) Competitors

GOSS vs. MOLN, IVVD, ABOS, OKUR, and YDES

How does Gossamer Bio compare to Molecular Partners?

Which has more risk & volatility, MOLN or GOSS?

Which has preferable valuation & earnings, MOLN or GOSS?

Do institutionals & insiders hold more shares of MOLN or GOSS?

Does the media favor MOLN or GOSS?

Is MOLN or GOSS more profitable?

Do analysts recommend MOLN or GOSS?

Summary

How does Gossamer Bio compare to Invivyd?

Which has preferable valuation and earnings, GOSS or IVVD?

Do analysts prefer GOSS or IVVD?

Does the media refer more to GOSS or IVVD?

Which has more volatility & risk, GOSS or IVVD?

Do insiders & institutionals have more ownership in GOSS or IVVD?

Is GOSS or IVVD more profitable?

Summary

How does Gossamer Bio compare to Acumen Pharmaceuticals?

Which has more volatility & risk, GOSS or ABOS?

Do analysts recommend GOSS or ABOS?

Does the media refer more to GOSS or ABOS?

Which has preferable earnings & valuation, GOSS or ABOS?

Do institutionals & insiders hold more shares of GOSS or ABOS?

Is GOSS or ABOS more profitable?

Summary

How does Gossamer Bio compare to OnKure Therapeutics?

Do analysts prefer OKUR or GOSS?

Does the media prefer OKUR or GOSS?

Do institutionals & insiders have more ownership in OKUR or GOSS?

Which has more risk & volatility, OKUR or GOSS?

Is OKUR or GOSS more profitable?

Which has higher earnings & valuation, OKUR or GOSS?

Summary

How does Gossamer Bio compare to YD Bio?

Do institutionals & insiders believe in GOSS or YDES?

Does the media refer more to GOSS or YDES?

Do analysts prefer GOSS or YDES?

Which has higher earnings and valuation, GOSS or YDES?

Is GOSS or YDES more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOSS vs. The Competition

Gossamer Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools